Bristol-Myers Suspends Study Drug Administration In Phase II Study Of BMS-986094

Bristol-Myers Squibb (BMY) Rose Past Resistance At The Highs

Bristol-Myers To Present At Bank Of America Conference; Webcast At 1:00 PM ET

Bristol-Myers Squibb (BMY) Has Broken Out To A New High For The Year

Bristol-Myers, Pfizer Announce Results From Subanalysis Of ARISTOTLE Trial

Trade BMY now with

8/1/2012 8:49 PM ET

Bristol-Myers Squibb Co.(BMY: Quote) announced today that the Company has suspended study drug administration in an ongoing Phase II study of BMS-986094 (formerly known as INX-189), a nucleotide polymerase or NS5B inhibitor in development for the treatment of hepatitis C.

This voluntary action was taken to protect patient safety based on the emergence of a serious safety issue. The cause of the safety issue and any potential relationship to study drug are unknown at this time, the company said.

The company noted that it is undertaking an immediate assessment of all patients in the study and following an evaluation of the patient data, will take appropriate actions.

Click here to receive FREE breaking news email alerts for Bristol-Myers Squibb Co. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 137 Articles Next>>

Editors Pick

Analog Devices Profit Meets Estimate; Outlook Weak

Analog Devices, Inc. said that its second quarter profit rose slightly from last year, helped mainly by lower income tax expenses even as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations. However, the company forecast third quarter revenue and earnings below analysts' current consensus estimates.

Stocks Close Modestly Higher Ahead Of Bernanke Testimony - U.S. Commentary

While buying interest was relatively subdued, stocks moved modestly higher over the course of the trading day on Tuesday. The strength on the day offset the weakness seen in the previous session, with the Dow and the S&P 500 reaching new record closing highs. The major averages gave back some ground in late-day trading but remained in positive territory.

Obama's Approval Rating Holding Steady Despite Scandals

While a recent series of scandals have caused headaches for the White House, the results of a Washington Post-ABC News poll released Tuesday suggest that the news has not had an impact on President Barack Obama's approval rating. The poll showed that 51 percent of Americans approve of the way Obama is handling his job as president compared to 44 percent that disapprove.